---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053931"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:58:16.962510+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q1 net loss $31.4M; cash $201.9M; pipeline on track for H2 2024 data

## Summary
- Net loss $31.4M ($0.42/diluted share) vs $27.7M ($0.58) in Q1 2023; R&D spend $27.4M up from $21.8M.
- Cash, equivalents & marketable securities $201.9M as of March 31, 2024; cash runway expected into 2026.
- PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) on track for initial proof-of-concept data H2 2024.
- PRT7732 oral SMARCA2 degrader expected to enter Phase 1 in H2 2024; IND-enabling studies ongoing.
- Appointed Sean Brusky as CBO and Robert Doody as SVP, IR in April 2024.

## SEC filing metadata
- accession: 0000950170-24-053931
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/0000950170-24-053931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/prld-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053931
- JSON: https://secwatch.observer/filing/0000950170-24-053931.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053931.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/0000950170-24-053931-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.